AxoGen

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AxoGen reports robust Q4 earnings, eyes growth through innovation

AxoGen's Q4 2022 performance showcased revenue growth, strong margins, and a focus on market expansion through core accounts.
The company's strengths lie in innovative products, high surgeon adoption rates, and a clear roadmap for future growth.
Challenges include post-COVID segment recovery, referral process acceleration, and balancing expenses with revenue.
Opportunities in rep productivity enhancement, product innovation, and regulatory milestones position AxoGen for continued success and market leadership.

AxoGen reports robust Q1 revenue growth and innovation focus

AxoGen's Q1 performance reflects strong revenue growth and market penetration strategies, supported by innovative product introductions and a clear outlook for future revenue and margin improvements.
While facing challenges in managing expenses and executing facility transitions, AxoGen's focus on niche market segments and commitment to R&D present opportunities for sustained growth and profitability.
Overall, AxoGen's strategic direction, emphasis on product innovation, and dedication to improving patient outcomes position the company well for long-term success and market expansion.

AxoGen reports revenue growth and product expansion in Q2

AxoGen's Q2 performance showed revenue growth, increased active accounts, and new product introductions.
Strengths include focus on Core Accounts, sales efforts, and no supply challenges affecting production.
Challenges include validation delay impacting gross margin and extended BLA submission timeline.
Opportunities lie in upcoming product launches, growth in scheduled procedures, and commitment to patient outcomes.

AxoGen reports robust Q3 growth driven by innovative nerve solutions

AxoGen's Q3 performance reflects strong revenue growth driven by emergent trauma and scheduled procedures, supported by a focus on core accounts and innovative products.
While challenges like a net loss persist, opportunities lie in market expansion, regulatory approvals, and maintaining revenue guidance, positioning the company for future success.
Investors should monitor AxoGen's ability to manage expenses, achieve profitability, and leverage its product innovations to drive sustainable growth and shareholder value.

AxoGen reports robust revenue growth, addresses supply chain challenges

AxoGen's strong revenue growth and product innovation demonstrate resilience and market potential.
While challenges like supply chain disruptions persist, the company's focus on cost management and customer relationships is key.
Opportunities lie in market expansion through new products and sustained revenue growth in the coming year.
Analysts are optimistic about AxoGen's performance and strategic direction, emphasizing the need for operational efficiency.

AxoGen reports revenue growth and innovation drive amidst challenges

AxoGen's Q1 2024 performance reflects revenue growth and strategic focus on core accounts and innovation. While challenges like net losses persist, opportunities lie in upcoming product approvals and enhanced transparency. The company's maintained full-year guidance indicates a positive outlook for revenue and cash flow.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions

Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings

ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. Additionally, organ and tissue donor Paul Flanders will be honored through a floragraph that will adorn the float. The parade will be held in Pasadena, CA on New Year's Day as part of the annual Tournament of Roses® celebration. This is the ninth year that Axogen has co-sponsored the Donate Life float to help raise awareness for the importance of organ and tissue donation.

Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation

ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET).

Axogen, Inc. to Participate at Jefferies London Healthcare Conference

AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates

Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Axogen: Q3 Earnings Insights

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2021.

Axogen, Inc. Reports 2021 Third Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021

Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during symposium session

Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand

RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft

Axogen RECON(SM) Clinical Study Completes Subject Follow-up

Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.

Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript

ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2021.

Axogen, Inc. Reports 2021 Second Quarter Financial Results

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference. The virtual presentation is scheduled for Wednesday, August 11, 2021 at 1:00 p.m. ET.

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

Axogen, Inc. Appoints John H. Johnson to Board of Directors

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021

Axogen Inc (NASDAQ: AXGN) has announced to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, pending ongoing discussions with the FDA regarding the regulatory classification of Avive, according to SEC filing. This announcement applies only to Avive, representing approximately 5% of Company revenue and has no impact on any other Axogen product, including the Avance Nerve Graft.

Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA

ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences.

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar?

ALACHUA, Fla. and TAMPA, Fla. , May 06, 2021 (GLOBE NEWSWIRE) --  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Peter J. Mariani, executive vice president and chief financial officer will present at the Canaccord Genuity Musculoskeletal Conference. The virtual presentation is scheduled for Thursday, May 20, 2021 at 11:00 a.m. ET.

Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference

Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat the estimate of ($0.16).

Recap: Axogen Q1 Earnings

ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2021.

Axogen, Inc. Reports 2021 First Quarter Financial Results

ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

News for AxoGen Stock (AXGN)